• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 6th March 2018

Cancer Survivorship Burden

A new paper entitled “Survivorship Burden for Individuals, Households and Society: Estimates and Methodology” has been published in the Journal of Cancer Policy. An article by OHE’s Paula Lorgelly and Margherita Neri will be published in a special issue of…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

A new paper entitled “Survivorship Burden for Individuals, Households and Society: Estimates and Methodology” has been published in the Journal of Cancer Policy.

An article by OHE’s Paula Lorgelly and Margherita Neri will be published in a special issue of the Journal of Cancer Policy. The issue focuses on cancer survivors and cancer survivorship and our article (available as open access) provides a review of the current evidence on estimates of cancer survivorship burden and presents methodology to inform future estimates.

With more and more people surviving cancer, it is important to estimate the economic burden that survivorship places on these individuals, as well as on their friends, family, carers and the wider society. Nonetheless, few studies at present have estimated the burden of cancer survivorship considering all the elements of burden and using a societal perspective.

The economic burden of the disease is the sum of the monetary value of the resources associated with treating the disease plus the cost of the lost opportunities due to the disease. As shown in the table below, for the case of cancer, the cost components associated with the disease burden can be either direct or indirect. The table also shows the type of ‘payer’ who usually faces each component of the burden. Health-related quality of life (HRQoL) is also an important burden to consider for both survivors and caregivers. 

  Cost Component ‘Payer’
Direct Costs Medical costs for primary treatment and long-term care Healthcare system / insurer
Out of pocket (OOP) costs Survivor (and family)
Indirect Costs Productivity loss Survivor (and family); Caregivers
Informal caregiving cost Caregivers
Health-related quality of life (HRQoL) losses Survivor; Caregiver

Among the available evidence on indirect costs of cancer burden, the authors found that: productivity loss is higher among individuals aged between 18 and 64, when patients experienced cancer at young ages and in patients with other comorbidities; the value of caregiving can be of a similar magnitude to direct medical cancer costs; physical HRQoL tends to be lower among cancer survivors who were diagnosed in childhood. Indirect costs are more difficult to estimate than the direct costs incurred by the health care system, particularly due to issues around data collection. However, they are no less important. A number of challenges include:

  • Difficulty identifying and sampling survivors who are not receiving active treatment, and identifying and sampling their caregivers;
  • Difficulty linking self-reported data on indirect cost and HRQoL with direct healthcare costs, while accounting for the substitution effect (i.e. informal care instead of professional care).

Possible improvements to the estimation of survivorship burden include:

  • Considering a control sample of patients without a history of cancer, in order to identify the marginal burden of disease;
  • Considering the variations of burden across stage and site of cancer, to reflect the heterogeneity of the disease.

Appropriately designed burden of illness studies, consistent with the taxonomy of the cost components, which encompasses improvements in estimation methodologies, will be pivotal to support policymakers in the allocation of resources and establish the future research agenda.

For more information please contact Paula Lorgelly at OHE. 

Lorgelly, P.K. & Neri, M., 2018. Survivorship Burden for Individuals, Households and Society: Estimates and Methodology. Journal of Cancer Policy. DOI

  • Health Data and Statistics
  • Measuring and Valuing Outcomes
  • External Publications

Related News

  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • April 2020

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Read more
  • News
  • April 2020

Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine

Read more
  • News
  • February 2020

Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!